About
Tri-Specific Nanobody
Areas of Focus
Categories
Biologics & Biopharmaceutical
Clinical Trials (9)
View allTotal Trials
9
As Lead Sponsor
9
As Collaborator
0
Total Enrollment
3,831
By Phase
PHASE3: 6PHASE1: 1PHASE2: 2
By Status
ACTIVE_NOT_RECRUITING: 3RECRUITING: 3COMPLETED: 2ENROLLING_BY_INVITATION: 1
Clinical Trials Pipeline9 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2021
2022
2023
2024
2025
2026
2027
2028
2029
Today
Hover over trial bars to see details
Recent Trials
NCT07007637Lead Sponsor
A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis Suppurativa
PHASE3Enrolling by invitation
835 participants
Started: Jun 27, 2025 · Completed: Jun 13, 2028
NCT06994936Lead Sponsor
An Open-label Study in Healthy Adults to Evaluate the Relative Bioequivalence of a Single-dose Administration of Sonelokimab Either by a Prefilled Syringe or an Autoinjector
PHASE1Active, not recruiting
120 participants
Started: Jun 5, 2025 · Completed: Oct 16, 2025
NCT06768671Lead Sponsor
An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)
PHASE3Recruiting
35 participants
Started: Dec 30, 2024 · Completed: Mar 27, 2026
NCT06641076Lead Sponsor
Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug
PHASE3Recruiting
960 participants
Started: Oct 15, 2024 · Completed: Jan 15, 2027
NCT06641089Lead Sponsor
Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response
PHASE3Recruiting
600 participants
Started: Oct 15, 2024 · Completed: Jan 15, 2027
Locations (1)
Headquarters
Zug, Switzerland
Map
Loading map...